Canada markets open in 3 hours 35 minutes

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3100-0.2400 (-5.27%)
At close: 04:00PM EDT
4.3400 +0.03 (+0.70%)
After hours: 04:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.5500
Open4.6100
Bid4.2600 x 200
Ask4.3500 x 100
Day's Range4.1850 - 4.6100
52 Week Range1.0800 - 5.0000
Volume669,419
Avg. Volume1,388,933
Market Cap224.979M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • GlobeNewswire

    G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET. The webcast of the event will be accessible on the Events & Presentations page of https://www.g1therapeutics.com/. About G1 TherapeuticsG1 Therapeutics, In

  • GlobeNewswire

    G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to t

  • Insider Monkey

    G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

    G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27. G1 Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]